Portal de Periódicos da CAPES

Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020

2020; European Centre for Disease Prevention and Control; Volume: 25; Issue: 11 Linguagem: Inglês

10.2807/1560-7917.es.2020.25.11.2000266

1560-7917

Anu Haveri, Teemu Smura, Suvi Kuivanen, Pamela Österlund, Jussi Hepojoki, Niina Ikonen, Marjaana Pitkäpaasi, Soile Blomqvist, Esa Rönkkö, Anu Kantele, Tomas Strandin, Hannimari Kallio‐Kokko, Laura Mannonen, Maija Lappalainen, Markku Broas, Miao Jiang, Lotta Siira, Mika Salminen, Taneli Puumalainen, Jussi Sane, Merit Melin, Olli Vapalahti, Carita Savolainen‐Kopra,

SARS-CoV-2 detection and testing

The first case of coronavirus disease (COVID-19) in Finland was confirmed on 29 January 2020. No secondary cases were detected. We describe the clinical picture and laboratory findings 3-23 days since the first symptoms. The SARS-CoV-2/Finland/1/2020 virus strain was isolated, the genome showing a single nucleotide substitution to the reference strain from Wuhan. Neutralising antibody response appeared within 9 days along with specific IgM and IgG response, targeting particularly nucleocapsid and spike proteins.